Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2009

View Archived Issues

Hydra raises financing to advance TRP ion channel programs

New serotonin reuptake inhibitors and 5-HT1A receptor antagonists discovered at Wyeth

Early phase II results show some activity with ARC-100 in pancreatic cancer patients

Roche discloses novel tachykinin NK3 receptor antagonists

Astellas Pharma divulges new prostanoid EP4 receptor agonists for PAD

New reverse transcriptase inhibitors for HIV presented in recent GSK patent

Bayer divulges new coagulation factor Xa and thrombin inhibitors for thromboembolic disorders

Auris Medical commences phase IIb AM-111 trial in hearing loss

FDA grants orphan drug status to omacetaxine for myelodysplastic syndromes

Oralair Grasses obtains pediatric marketing authorization in Germany

AGI completes patient enrollment in phase III study of Rezular in IBS-D

NexBio completes phase I clinical trial of influenza drug Fludase

Intercell plans to initiate a phase III clinical trial of TD vaccine in April 2009

Mesoblast initiates first human trial of stem cell treatment in knee osteoarthritis

Metabasis refocuses product pipeline as part of corporate restructuring

Bilastine as effective as desloratadine in seasonal allergic rhinitis

Antitumor activity increased with PLX-4032, capecitabine and bevacizumab in colorectal cancer model

Obecure completes enrollment in confirmatory phase IIb Histalean trial

Synergy seen with PARP-1 inhibitor BSI-401 and oxaliplatin in pancreatic cancer model

Nile to focus on development of CD-NP and CU-NP and terminate 2NTX-99 program

Cleveland completes dosing of fourth cohort in safety study of Protectan CBLB-502 for ARS

Abraxis plans to create Abraxis Health, focused on personalized medicine

Grifols obtains minority stake in Cardio3

RoActemra approved in the E.U. for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...